Yesterday, a jury determined all claims of Merck's (NYSE: MRK) HCV nuc patents to be valid. If MRK's claims remain ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE